Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Theratechnologies-Beaufour Ipsen agreement on TH-9506

Oct. 25, 1996

Bristol-Myers Squibb describes potent and selective beta3-adrenoceptor agonist

Oct. 25, 1996

Lilly claims compounds for menopausal disorders

Oct. 25, 1996

Antiobesity proteins described by Lilly

Oct. 25, 1996

First and only Estrophasic oral contraceptive approved

Oct. 18, 1996

Menorest approved in Belgium

Oct. 18, 1996

Serono's recombinant human growth hormone approved

Oct. 18, 1996

JT and Tularik to develop new antidiabetic agents

Oct. 18, 1996

Novo Nordisk enters collaboration on PTPase inhibitors

Oct. 18, 1996

U.S. patent covers Celtrix's SomatoKine

Oct. 18, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...